Xilio Therapeutics, Inc.XLONASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank50
3Y CAGR-7.6%
5Y CAGR+1.3%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
-7.6%/yr
Annual compound
5Y CAGR
+1.3%/yr
Recent deceleration
Percentile
P50
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
1 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$46.75M+13.4%
2024$41.21M-21.0%
2023$52.14M-11.9%
2022$59.20M+15.7%
2021$51.19M+16.6%
2020$43.91M+208.0%
2019$14.26M-